Thymosin Alpha-1 vs LL-37
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Ta1, Zadaxin
A naturally occurring thymic peptide that enhances immune function. Approved in over 35 countries for hepatitis B/C and as an immune adjuvant.
Also: Cathelicidin, CAP18
A naturally occurring antimicrobial peptide and the only human cathelicidin. Part of the innate immune system with broad-spectrum antimicrobial activity.
Key Comparison Insights
- Both peptides belong to the Immune category, suggesting similar primary applications.
Detailed Comparison
| Attribute | Thymosin Alpha-1 | LL-37 |
|---|---|---|
| Category | Immune | Immune |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Thymosin Alpha-1 modulates T-cell function, enhances dendritic cell maturation, and promotes Th1 immune responses. It increases IL-2, interferon-alpha, and interferon-gamma production while reducing inflammatory cytokines. | LL-37 directly kills bacteria, fungi, and some viruses by disrupting their cell membranes. It also modulates the immune response, promotes wound healing, reduces inflammation, and has anti-biofilm activity against bacterial infections. |
| Common Dosing | 1.6 mg twice weekly 2-3x weekly | 100-200 mcg daily Once daily |
| Administration | Subcutaneous injection | Subcutaneous injection or topical |
| Typical Duration | 6-12 months for hepatitis | Variable by protocol |
| Best Time to Take | Morning | Morning |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Approved internationally for chronic hepatitis B and C. Studies show improved outcomes when combined with chemotherapy for cancer. Research demonstrates benefits in sepsis, immunodeficiency, and vaccine response enhancement. | Research demonstrates broad antimicrobial activity including against antibiotic-resistant bacteria. Studies show wound healing benefits, anti-biofilm effects, and immune modulation. Being investigated for chronic infections and wound healing applications. |
Frequently Asked Questions: Thymosin Alpha-1 vs LL-37
What is the difference between Thymosin Alpha-1 and LL-37?
Thymosin Alpha-1 is a immune peptide that a naturally occurring thymic peptide that enhances immune function. approved in over 35 countries for hepatitis b/c and as an immune adjuvant. LL-37 is a immune peptide that a naturally occurring antimicrobial peptide and the only human cathelicidin. part of the innate immune system with broad-spectrum antimicrobial activity. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Thymosin Alpha-1 or LL-37?
Neither is universally "better" - the choice depends on your specific goals. Thymosin Alpha-1 is typically used for immune purposes, while LL-37 is used for immune. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Thymosin Alpha-1 and LL-37 be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Thymosin Alpha-1 and LL-37 together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.
Related Comparisons
View Full Peptide Profiles
Educational Information Only
This comparison of Thymosin Alpha-1 and LL-37 is for educational purposes only. Neither this comparison nor any information on this site constitutes medical advice. Always consult with qualified healthcare providers before making decisions about peptides or other substances.